SillaJen, Inc. (215600.KQ)
KRW 2565.0
(0.79%)
KRW 2565.0
(0.79%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 19.4 Billion KRW | -20.83% |
| 2022 | 24.5 Billion KRW | -8.49% |
| 2021 | 26.77 Billion KRW | 9.11% |
| 2020 | 24.54 Billion KRW | 180.42% |
| 2019 | 8.75 Billion KRW | -68.86% |
| 2018 | 28.1 Billion KRW | -14.85% |
| 2017 | 33 Billion KRW | -56.66% |
| 2016 | 76.15 Billion KRW | 15.23% |
| 2015 | 66.09 Billion KRW | -46.84% |
| 2014 | 124.32 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 19.92 Billion KRW | 1.88% |
| 2024 Q1 | 19.55 Billion KRW | 1.85% |
| 2023 FY | 19.4 Billion KRW | -20.83% |
| 2023 Q3 | 21.28 Billion KRW | -13.18% |
| 2023 Q1 | 23.91 Billion KRW | -2.42% |
| 2023 Q4 | 19.2 Billion KRW | -9.8% |
| 2023 Q2 | 24.51 Billion KRW | 2.53% |
| 2022 Q2 | 24.16 Billion KRW | -11.88% |
| 2022 Q4 | 24.5 Billion KRW | -0.96% |
| 2022 FY | 24.5 Billion KRW | -8.49% |
| 2022 Q3 | 24.74 Billion KRW | 2.41% |
| 2022 Q1 | 27.42 Billion KRW | 2.39% |
| 2021 FY | 26.77 Billion KRW | 9.11% |
| 2021 Q2 | 24.36 Billion KRW | 1.79% |
| 2021 Q3 | 25.89 Billion KRW | 6.28% |
| 2021 Q4 | 26.77 Billion KRW | 3.42% |
| 2021 Q1 | 23.93 Billion KRW | -2.47% |
| 2020 Q4 | 24.54 Billion KRW | -30.51% |
| 2020 FY | 24.54 Billion KRW | 180.42% |
| 2020 Q3 | 35.32 Billion KRW | 21.25% |
| 2020 Q2 | 29.12 Billion KRW | 126.05% |
| 2020 Q1 | 12.88 Billion KRW | 47.23% |
| 2019 FY | 8.75 Billion KRW | -68.86% |
| 2019 Q4 | 8.75 Billion KRW | -90.72% |
| 2019 Q3 | 94.33 Billion KRW | 3.18% |
| 2019 Q2 | 91.42 Billion KRW | -14.22% |
| 2019 Q1 | 106.58 Billion KRW | 711.25% |
| 2018 Q4 | 13.13 Billion KRW | -10.24% |
| 2018 Q2 | 12.67 Billion KRW | -14.87% |
| 2018 Q3 | 14.63 Billion KRW | 15.48% |
| 2018 Q1 | 14.88 Billion KRW | -2.35% |
| 2018 FY | 28.1 Billion KRW | -14.85% |
| 2017 Q2 | 42.28 Billion KRW | -24.67% |
| 2017 Q1 | 56.12 Billion KRW | -2.72% |
| 2017 Q4 | 15.24 Billion KRW | -55.52% |
| 2017 Q3 | 34.27 Billion KRW | -18.92% |
| 2017 FY | 33 Billion KRW | -56.66% |
| 2016 Q2 | 84.46 Billion KRW | 16.15% |
| 2016 Q4 | 57.69 Billion KRW | -24.86% |
| 2016 Q3 | 76.78 Billion KRW | -9.1% |
| 2016 Q1 | 72.72 Billion KRW | 10.03% |
| 2016 FY | 76.15 Billion KRW | 15.23% |
| 2015 Q1 | 107.74 Billion KRW | -13.34% |
| 2015 Q3 | 87.4 Billion KRW | -1.71% |
| 2015 Q4 | 66.09 Billion KRW | -24.38% |
| 2015 Q2 | 88.92 Billion KRW | -17.47% |
| 2015 FY | 66.09 Billion KRW | -46.84% |
| 2014 FY | 124.32 Billion KRW | 0.0% |
| 2014 Q4 | 124.32 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Co., Ltd. | 169.47 Billion KRW | 88.552% |
| iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -931.766% |
| BINEX Co., Ltd. | 75.68 Billion KRW | 74.367% |
| Bioneer Corporation | 80.61 Billion KRW | 75.932% |
| Anterogen.Co.,Ltd. | 19.98 Billion KRW | 2.931% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | 85.707% |
| CrystalGenomics, Inc. | 97.82 Billion USD | 80.167% |
| Helixmith Co., Ltd | 73.55 Billion KRW | 73.625% |
| Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 98.186% |
| Medy-Tox Inc. | 137.14 Billion KRW | 85.853% |
| Peptron, Inc. | 16.36 Billion KRW | -18.523% |
| Amicogen, Inc. | 248.12 Billion KRW | 92.181% |
| Genexine, Inc. | 79.68 Billion KRW | 75.652% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | 33.731% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | 53.003% |
| ALTEOGEN Inc. | 108.25 Billion KRW | 82.079% |
| PharmaResearch Co., Ltd. | 73.08 Billion KRW | 73.455% |
| JETEMA, Co., Ltd. | 179.09 Billion KRW | 89.167% |
| OliX Pharmaceuticals,Inc | 52.48 Billion KRW | 63.038% |
| Genomictree Inc. | 7.81 Billion KRW | -148.34% |
| MedPacto, Inc. | 9.56 Billion KRW | -102.817% |
| D&D Pharmatech | 23.98 Billion KRW | 19.114% |
| EASY BIO,Inc. | 105.86 Billion KRW | 81.675% |
| GI Innovation, Inc. | 9.63 Billion KRW | -101.334% |